Cyclophosphamide
B-Cell Neoplasm
University Hospital, Basel, SwitzerlandSmall moleculePhase 2Active
BB
66/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 52/ 100
- Competitive Position
- 89/ 100
Competitive context
47 Active assets in the B-Cell Neoplasm cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Zanubrutinib Curis, Inc. | Phase 2 | BB |
Inno-206 Curis, Inc. | Phase 2 | BB |
PREDNISONE TABLETS Curis, Inc. | Phase 2 | BB |
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER Curis, Inc. | Phase 2 | BB |
Obinutuzumab BeOne Medicines | Phase 1/2 | B |
View all 50 →
Same molecule, other indications
Cyclophosphamide is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →